title: Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.
authors.forename: M K
authors.initials: MK
authors.lastname: de Vries
authors.forename: E
authors.initials: E
authors.lastname: Brouwer
authors.forename: I E
authors.initials: IE
authors.lastname: van der Horst-Bruinsma
authors.forename: A
authors.initials: A
authors.lastname: Spoorenberg
authors.forename: J C
authors.initials: JC
authors.lastname: van Denderen
authors.forename: A
authors.initials: A
authors.lastname: Jamnitski
authors.forename: M T
authors.initials: MT
authors.lastname: Nurmohamed
authors.forename: B A C
authors.initials: BA
authors.lastname: Dijkmans
authors.forename: L A
authors.initials: LA
authors.lastname: Aarden
authors.forename: G J
authors.initials: GJ
authors.lastname: Wolbink
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis*; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000276:immunology* / Q000627:therapeutic use; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab